Active agent and medicine containing it, for preventing or combating organ graft rejection in humans.

摘要

The drug is characterized in that it contains a monoclonal antibody capable of attaching itself to the human interleukin 2 receptor carried by the lymphocytes and in that it is not cytotoxic in vitro, even in the presence of a complement, while inhibiting cellular proliferation induced by interleukin 2, in particular the 33B3.1 antibody.